. ..nJ‘_'.’-"
`
`PU
`
`
`
`.5
`In
`
`
`MIIWM
`lJ!lli|J.|lflJM|
`
`D._.__
`I'L|
`
`OF THE
`
`JD
`
`
`
`In43:2—
`Eu:
`3;? INTERSCIENCE CONFERENCE ON ANTIMICROBIAL
`I i
`=3
`AGENTS AND CHEMOTHERAPY
`
`SEPTEMBER 24-27, 1998
`
`SAN DIEGO, CALIFORNIA
`
`ASM's Annual Meeting on Infectious Diseases
`
`"- .
`£SX'€it'ICA.r7
`--
`
`- 0 .- T ‘FF
`rh.‘ f.‘,»LirIT" IL(91Ir"
`
`
`MYLAN - EXHIBIT 1011
`
`

`
`
`
`ABST
`
`
`
`C i
`
`O F
`
`T H E
`
`a3mazaE;::u::»xa
`$‘T:$.¥J?f}?%§"?
`
`*5
`
`‘
`
`».,.T'»%
`
`
`
`Ff !'r<%:3, Lie?
`
`381th QNTERSCIENCE CGNFERENCE GN ANTIMICRQTBIAL
`
`“W”
`
`_=
`
`AGENTS AME QHEMOTHEREAPY
`
`SEPTENWER 24-27,1998£
`
`SAN DIEGO, CALEFORNIA
`
`LLLLLL“‘“'
`
`A$M’a Annual Meeting on lrfiectieus Diseasas
`
`
`
`Q 3 »EM£S1(IAN
`.,,, mcuzry '
`M5CR§S,E..
`
`-
`
`cxv
`
`

`
`CONTENTS
`
`1 998 Abstracts, by Category
`
`E.
`
`G.
`
`A. Pharmacokinetics and piiarmacodynamics in
`aninialsoi
`B. Animal models, pathogenesis of infectious diseases,
`molecular basis for pathogenicity
`.
`.
`.
`.
`C. Antimicrobial resistance and action: genetics,
`mechanisms,
`D. Laboratory tests (excluding viral) for diagnosing infections;
`methods for susceptibility
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`in vitro antimicrobial susceptibility studies-, srarveiliance and detectson
`of antimicrobial resistance; drug interactions and combinations
`F. New antimicrobials (pre US IND) including
`chemistry and
`Immunology and host defenses; bacterial vaccines,
`immunomodulatots, and immune response
`H. Virology (non—HIV): diagnostics, pathogenesis, epidemiology,
`natural history, antiviral drugs, vaccines, and clinical trials
`I. HiV and other retroviruses and complications of AIDS............................363
`.
`.
`.
`.
`.
`.
`.
`.
`I. Mycology: diagnostics, susceptibility, pathogenesis, epidemiology,
`"31
`natural history‘, antifungai drugs and clinical trials
`K. Nosocomial. and surgical infections and related. epidiemiiologicail studies ..499
`.
`.
`.
`.
`.
`.
`L. Comrnimity—acquired intentions,
`OB GYN and
`STD infections, and related epidemiological studies ...............i....£..,........547
`M. Clinical trials of antimicrobial agents
`...................587
`N. Unique and instructive clinical observations
`....................¢.,”............587
`O. Pharmacoeconomics and managed care ..........................,........,.................605
`Invited Speakers
`S. Symposia and Special Lectures...................................i..............................617
`
`Keyword
`
`s
`
`F‘-"d"=1¥=
`
`%2'Ef
`9
`tn-fetti
`pneu"
`H. ER
`FWMC
`KRIS l‘l
`36812H(3
`Dmma,
`Backgn
`g‘R?‘)
`ef;::t::
`to ex“.
`'?"fl‘ib§“
`gnngfitrfi
`employ
`NMRI
`were U}
`pm 5;,
`d(‘1fff"«T°’
`e
`or I
`raw“;
`after i;
`
`PRP in
`
`geoeilcg
`els con
`.h._,.ti,
`PSP at
`
`I
`
`Cfltha‘
`ticular
`
`A-3.
`Fharr
`Expe.
`I. l..U'|
`GHAI
`Med.
`We c\
`effect:
`tal me
`Metht
`
`
`
`outcropnabouteurnsnocolooanaoaotuununuuauoésé
`‘
`IV
`.- 7-
`'-
`-
`"
`
`9'I‘.A\NF()iH) l"‘ill\"F.RS1’T‘Y
`l.A.'\i'E .\lf13I(l.\l. IJBR.-\RY
`
`

`
`ay——-—~
`
`—»
`
`-
`
`__MiSESSlON198;-A, Paper A-124 ° Sundfll
`
`198—A. Poster Session
`.
`,
`,
`,
`Pharmacokinetics In Animals
`
`Sunday, 1:30 pm
`Exhibit Hall
`—~—-
`
`—-
`
`-
`
`“T2 “’°‘°
`lS used for
`sulted in a
`=rSus 2033
`suited in a
`8 nghr/mL,
`Sm” 33%
`1 E,
`n,,::,:,a(‘51_§
`Valucs was
`Ill‘-istfatioll
`
`_ " ,
`bol1?!" Fhd
`‘C°km‘_mc3‘ _
`5}” ‘m°m3'
`'ty of “Z
`
`‘cytosine
`mdidiasis
`
`_
`_
`W‘5°°“5“‘I
`
`I El'mination of Bay 12 8039
`I t
`9
`ill‘€23
`'th 1'
`t'
`I
`-
`n es ma
`e ransepi e ia
`(Bay) (Moxiiloxacin) in Rabbits.
`E. RUBINSTEIN, A. MUSAFIJA, Y. STEHLMAN, A. BARZILAI, S.
`SEGEV, Sch. of Med., Tel-Aviv Univ., Israel.
`Thetrans-epithelial intestinal elimination (TEIE) of Bay was measured
`in the jejunum (=]), ileum (=Il) and caecum (=-C), and in the bile in a
`rabbit model. Segments from the J, ll, and C were created along with
`their intact blood supply and the main bile duct and the jugular vein
`were cannulated. The contents of the intestinal segments were collect-
`ed over a 120 min. period along with the secreted bile following a sin-
`gle systemic administration of Bay 15 mgllzg. Peak serum level was
`3.1(:1.1) mg/L (at 15 min) The TEIE constants of Bay were: 0.019
`{eD.017) in the J; 0.01 1 (1: 0.014) in the II and 0.002 (:0.002) mcg.cm
`'3.min ‘l in the C. Per loop, the eliminated quantities of Bay over 120
`min were: 9.59 (39.37) in the j; 8.26(:6.74) in the IL and 1.9Z(:».l.86)
`mg in the C. Calculated per cm2 surface of the intestinal wall, the
`eliminated quantities were: 2.30(:2.02)in the J; 1.29(:1.64) in the IL
`and 0.264(:0.255) mcg/cm’ in the C. Biliary Bay conc. varied between
`3.30-5.16 mg/L during the 120 min period. Intestinal Bay conc. par-
`llleled serum Bay levels while biliary levels exceeded the serum levels
`item 45 min. onwards. Altogether it was calculated that ~4.5% of the
`My dose were eliminated by TEIE in the digestive tract over the 120
`min experimental period, similar to the TEIE of ciprofloxacin mea-
`lured in the same model.
`
` 1.‘-
`
`aureus were >16 ug/mL. Excretion:
`metabolites against S.
`[“’C]Linezolid (25 mg/kg po, acetamide label) was closed. Most of the
`radioactivity was recovered within 24 h. Total urinary excretion was
`74.7 1 2.0% of dose. Feces contained 23.6 -.1: 1.1% of dose.
`Radioactive carbon dioxide in expired air made up 2.7% of dose.
`Total recovery was 98.9 1 1.4% of dose. Intaurocholate-supplemenb
`ed, bllfl-CXtC.l'lOl'lZ£d rats, radioactivity recovery was 95.2% with
`15.6%, 6.7% and 72.9% of dose recovered in bile, feces and urine,
`respectively. In summary: Linezolid is a bioavailable and widely dis-
`tributed antibiotic that is subject to renal tubular reabsorption and is
`excreted primarily in urine as parent drug, or as carboxylic acid
`metabolites that have low antibacterial potency.
`
`A-124“
`lmpact of Neutropenia in Tissue Penetration of
`Moxifloxacin (MOX) and Sparfloxaein (SPX) in infected
`Mice.
`
`‘Clinical
`R. GARRAFFCN, C. ROPTiNl, and A. BOUDJADJAZ,
`Pharmacokinetics Unit, Univ. Hosp., Nice, France; 2 Bayer Pharmacy,
`Puteaux, France.
`Most of fluoroquinolones are able to concentrate intracellularly in
`phagocytic and non phagocytic cells, reaching concentrations several
`times higher than extracellular concentrations. MOX, a novel fluoro-
`quinolone with a broad and high activity against Gram positive bac-
`teria, Gram negative, anaerobes and intracellular pathogens, shows
`PMN’s concentrations 9 to 10 fold higher than in extracellular fluids.
`In order to assess if neutropenic could result in a reduction of tissue
`penetration we compared, in normal and neutropenic mice with pneu-
`monia ancl peritonitis, the Cmax and AUCS of MOX and SPX in the
`infected tissues. MOX shows highest penetration ratios than SPX in
`lung (4.96 vs. 2.42) of non neutropenic and neutropenic mice (3.76
`vs. 2.05). The results are comparable for peritonitis. Moreover, when
`we look at the ratios for AUCs and Cmax in normal versus neu-
`ttopenic mice, we observed that in lung (1.25 vs. 1.64) as in peri-
`toneum (1.10 vs. 1.55), neutropenia reduces more consequently the
`tissue penetration for SPX than for MOX The results obtained with
`Cmax are in agreement with these data. Diffusion of quinolones at the
`infective sites probably use two different mechanisms: lipid solubili-
`ty-induced diffusion through biological membranes, and penetration
`into macrophages which act as natural vectors. Positive tissue/plasma
`ratios confirm good tissular penetration for both quinolones. With
`regard to the polynuclears carriage, it seems that SPX is more influ-
`enced by the presence or the absence of PMN’s than MOX
`
`have been
`have been
`termine (1)
`the magnin
`s known of‘
`ieutropenif
`’ 123
`pharmactfl
`'
`' 9
`I and peak
`lhsatption, Distribution, Metabolism, and Excretion ail
`_-the Oxazoiidinone Antibiotic Linezoiid (PNU-100766) in
`’;{f§:f'§f,..
`_'ll1e Sprague Dawley Rat.
`3, pharmaj
`it cures, KL. resnsrmx, 5.0. SLATER, RT. DALEY-YATES,
`5. ‘1n€ect'~-
`].N. DUNCAN, EB. FAGERNESS, M.R. HOVVARD, L}. MARTIN,
`fycast cell!
`OZAWA, B.]. PASSINGHAIVI, H.G. PARKS, G.W. PENG, RJ.
`were treat-
`; IILEIMONDS, W. SPEED, D. YALLOP, s. YAMAZAKI, Pharmacia 8c
`n 1.56-40‘
`-Upjohn, Kalamazoo, MI.
`. lncreasin‘
`.'
`iiitlezolid is an oxazolidinone antibiotic in clinical development for
`mgmg f'°m.
`Inlttnent of infections due to susceptible and antibiotic-resistant
`d from .6"
`mt dosm "film positive bacteria. As part of preclinical safety assessment,
`91"‘ Flat?‘ .
`£flJME studies were‘ done in Sprague Dawley rats after single 25
`ma m- i
`,'
`_ pgilrg po or 10 mg/kg iv doses. Pharmacokinetics and Absorption:
`*7’ h°w°V,
`1
`-{hr a 10 mg/kg iv dose, plasma concentrations decayed biexponen-
`met" wt,“ I -i - with a terminal
`tm of 1 h. Plasma clearance was 10.5
`MIC R
`'flJminlkg. After a 25 mg/kg po dose, absolute bioavailability was
`“aloefflca L
`3.1939/o. Cmax was 15.8 ug/mL. Concentrations > S. aureus MIC were
`25 /° °f t "
`-haintained to 4-8 h. Tmax was at 0.3-1.0 h. Extensive renaltubular
`'
`.rption of parent drug was observed. Radioactivity circulated
`is
`L
`.
`ily as parent drug. Distribution: The volume of distribution
`_
`as) was 0.72 L/kg after an iv dose. Radioactivity was widely dis-
`.>'Iil,*-uted, with lower levels in brain, eyeball, white fat, mineral bone
`testis. Tissues containing radioactivity higher than the plasma
`.- ' e liver, kidney, adrenal and GI’ tract. Binding of Linezolid to- plas-
`u proteins was 32%. Metabolism: Radiometric HPLC profiles
`"-_--.- Ned that Linczolid (po) was excreted mostly as intact drug (32%
`dense) and was metabolized by morpboline ring oxidation to ring-
`=___.-.- ed major metabolites PNU-142300 (30% M and 21% F) and
`I
`_
`-142586 (5~7%), PNU-173558 (a metabolite of PNU-142586,
`v’ r L and PNU-143131. (a byproduct of ‘PNU-142300 formation, 4-
`.5- M. Feces contained primarily metabolites. Other minor metabolites
`.._lfiI’h not individually exceed 2 % of dose. The MIC’s of the above
`
`
`
`I
`_
`
`‘-
`
`CATEGORY A 0 Pharmacalzinetics and Pharmacodynamic: in Animals or Human:
`
`39
`
`
`
`-
`
`

`
`CHUACHOOWONG, R. — 126-1.1-144
`CHUARD, C. — 25-D.D-1
`CHUCK, s.K. — 180-0.0-27
`CHUL, — 33-H.H—33
`CHUNG, A. — 87-H.H-64
`CHUNG, D.R. — 36-K.K-26, 74-E.E-55
`CHUNG, 1. — 48-EF-31
`CHUNG, w.O. — 99-D.D-39
`CHURCH, D. -- 131-L.L-83
`CHURCH, 1. — so-1.1-35
`CHURCHYARD, A. - 153-L.L-113
`CHUV, — 199-J.)-1453, 214-13.13-75, .95-C.C-103
`CHYOU, 1>. — 17—C.C-27
`CIABATFI, R. - 148-EF-107
`CICHERO, P. ~ 119-D.D-94
`CICIRELLO, H.G. — 86-G.G-31
`C1EsLAK, P. — 144-1_.1.-93
`C1LENTO, 3.]. — 166~I.I-187, 51-1.1-55
`CIMOCHOSKI, C.R. — 149-EF-122
`CXMOCHOWSKI, C. — 149-EE-128
`CINATL, 1. — 137—A.A-70, 151-H‘.H-95
`CTNATL JR, 1. -- 125-1.1-145, 137-A.A-70,
`151-H.H—95, 151-H.H—96
`CINGOLANI. A. — 119-D.D-107, 21-L.L-9,
`216-Ll-Z73, 218-K.K-148
`CIRAVEGNA, B. — 67-LL-31
`CIRIA, L. — 127-1.1-155
`C1R1NC1oNE, B. — 15-A.A-23
`CISIH HAUTE NORMANDIE, — 33-H.H-28
`C1sNAL, M.C. — 97-C.C-143
`C1sNEROs, J.M. - 107—G.G-53, 143-K.K-83
`CTSTERNA, R. — 129-K.K-72, 129-K..K-73
`CTTRO, D.M. — 48-F.F-43
`CITRON, D. — 77-LL-65
`CITRON, D.M. — 122-E.E~147
`C1L11=E1, A. — so-1.1-43
`CIUPEK, C. - 94—C.C-87
`CLAAHSEN, H. — 20-K.K—23a
`CLAFEE, D.PL — 87-H.H-57
`CLANCY, C.1. — 152-K.}(-98
`CLARDY, 1. — 200~F.F-186
`CLARK, C.L. — 175-E.E-156, 72-E.E-24
`CLARK, D. — 30-EE-13
`CLARK, J. - 117-13.3-45
`CLARK, }.M. _ 172-B.B-63
`CLARK. N. — 9-4-C.C-96
`CLARK, R. - 149-F.F-126, 203-1.1-233, 203—I.I—236,
`52-1.1-67 ,
`CLARK, R.1=. — 149-1=.1~"-125
`CLARK, s. — 105-EE-97, 122-E.E-133, 53-K.K-43
`CLARKE, A.M. _ 119-D1)-97
`CLARKE, S.C. — 15-11.11-1'1
`CLAROS, MLC. — 1%1—E.F.—1‘7"/
`CLAs, D. — 66-K.K-54
`CLASS, R. - 185-F.i-‘-182
`CLAssEN, D.C. — 24-0.0-3
`GAVE, D. - 96-K.K-68
`CLAVEL, F. — 63-1.}-82
`CLAYETFE, 1>. - 49-1.1-22
`CLEARY, T.G. - 15-13.1;-14
`CLEAVINGER, P.j. — 32-H.H-9
`CLEGG, 1. — 150-'r‘.‘P—‘l as
`CLEMENS, R. — 186-H.H-133
`CLEMENTs, D.A. - 32—H.H-14
`CLEMENTs, 1. - 93—B.B—34
`CLEMONS, K.v. - 109-1.1-64, l09—1.]~65, 109-1.1-70,
`39-14-51, 39-11-52
`CLERICI, M. - 64-LI-93
`CLEsCA, P. — 151-H.H-101
`cLEvEN15E.EGH, P. — 12—G.G-5
`CLEVENBERGH, P.H.—131-LL-85, 131~L.L-86
`CLIFFORD, D.B. - 212-1.9149
`(SUMO, ML. - 114-E1:-7:
`CLOSE, 51>. — 109-1.1-75
`CLOTET, 3. — 128-LL 153, 141-1.1.177, Z02-LI-Z16,
`205-1.1-25o, 52-1.1-65, 54-1.1-92
`CLUMECK, N. — I67-1.!-I97, 205-1.1-247', 31-G.G-13.
`ss-1.1-101
`COAKLEY, D. — 13-1.1-9, as-1.1-107, 88-LI-108
`COAKLEY. ‘W. - 27-D.D-22
`COATEs, P. — 18—C.C—34, 73-E.E—51a
`C0KYES."1‘.j. — 127-1.1-160
`COBB, L. — 67-LL-34
`COB0, 1=. — 129-KK-79a
`C080, 1. — 125-1.1-139, 125-11-143
`COBO, M.E. —125~1.1-143
`COBO, N. ~ 20-K.K-20
`(20130, R. - 90-K.1(-62
`
`COCHEREAU, 1. — 172-11.13-59
`COCKERILL 111, ER. — 27-DD-23
`COEL1-1O, K.l.R. — 33-H.H-29
`COETSIER, C. — 119-D.D-104
`COFFINIER, C. — 153-L.L-111
`COGGON, G. — 140-H.H-87
`COGHLIN, G. - mo-E.E-64
`COHEN, C.J. — 204-1.1-245;
`COHEN, 1. — 12-G.G-11, 172-3.357, 31-G.G-25a,
`67-L.L—32
`COHEN, M. — 66-K.K-51
`COHEN, M.J. — 171-A.A-100
`COHEN, R. — 154-MN.MN-43, 71-C.C-76
`COHEN, s. — 73-E.E-46
`COHEN, S.H. .- 76-L.L-55
`COHEN, Y. — 189-1.1-140
`COHEN STUART, Lw. — 166-1.1-180,51-1.149
`COHEN STUART, ].W.T. - 51-1.1-so
`COHN, 1. — 24-0.0~8
`COHN, s. — 170-MN.MN-so
`CO11=1=1ER, 13. — 133-DD-117
`COLAms, D. — 23-L1.-20
`COLBVH, THE — 153-L,L-114
`COLE, s.1=. - 153.13-15, 16-B.B-16
`COLEMAN, K. — 105-F.F-100, 105~F.F-98
`COLGROVE, R.C. — 13-1.1-5
`COLLADO, A. - 125-1.1-131, 125-1.1-141
`COLLATZ, E. - 118-C.C-158, 173-C.C-172, 173-
`C.C-174b, 61-C.C-54
`COLLAZO, 1. - 12.5-1.1-143:
`COLLEDGE, D. — 201-H.H-159
`COLLET, L. _ 129-K.K-76
`COLLIDA, A. — 123-E.E-15o
`COLLIGNON, L. — 12-G.G-6
`-
`COLODNER, R. — 21-L.L-1
`COLOMBO, A.L. - 138-1.1-129, 139-1.1-142
`COLONNO, R. — 49-11-20, 53-11-79
`COLONNO, R.]. — 62-H.H-49
`COLsON, P. - 169-LL-123
`COMOL1, P. — 140-H.H-89
`COMPTON, s. — 150-EF- 135
`COMTE, F. — 103-C.C-150
`CONCIA, E. - 102—A.A-62
`CONDE, M. — 93-D.D-s2
`CONDE, R. - 189-1.1-138
`CONDREAY. L.D. — 62-H.H-5i
`CONEJO, M.c. ~ 179-K.K~123
`CONLY, ].M. — 14~—K.K-9
`CONNELLY, EL. — 32-H.H-5
`CONNELLY, G. - 134-EE-163
`CONNTCK, L. — 166-[.1-188
`CONNOR, E. — 62-H.H—50, 91-MN.MN-20
`CONNOR, 3. -- 101—A.A~60, 1<31~A.A-63
`CONRAD, 1>. — 4-11.5-9
`CONSOLINI, D.M. - 144-LL-93
`CONsTANm~1, M.N. - 20—K.K-I 3
`CONTANT, <1 — ma-but-13
`CONWAY, B. - 165-1.1-189,205-1.1-253
`COOK, C. — 119-D.D-91
`COOKE, R. — 122-E.E-131
`COOMBS, G.w. — 94-C.C-89
`COOMBS, R. — 206-1.1-251
`COONAN, K. — 62-H.H-53
`COOPER, A.1>. — 201-H.H-150
`COOPER, D. ~ 25—D.D—3, as-1.1-105
`COOPER, D.A. — 1-1., 135-1., 166-1.1-185, 212-1.
`51-11-55, 51-11-53, 5-1, 38-1
`COOPER, K.D. — 111-MNMN-23
`COOPER, R. — 204-1.1-245, as-1.1-103
`COOPER, R.D.G. -148~F.F-110
`COPIN, 1>. — 36-K.K-25
`COPLAN, P. — 186-H.H-127
`CI31?ul\I,?.M.—- menu;
`COPLAND, M. - 215-1.1-254
`CORBEKL, L3. - 106-G.G~37
`CORBELLA, x. - 179-K.K-124, 20-K.K-19
`CORCORAN, E. — 109-1.{-63, I72-8.8-6!
`CORDERO, E. — 125-11-141, 143-K.K~83
`CORDOBA, 5. — 217-1.1-154, 74-E.E-63b
`CORDONNIER, C. — 68-LL-41
`COREY, C.R. — 43-3.320
`COREY, L. - no-H.H-32, 155-11.11-122, 166-I,
`166-1.1-190, 51-L1-57, 91-MN.MN-20
`COREY, 1>. — 62-I-LH-44, 76-L.L-49
`CORNAGUA, G. — 120-EE-100, 123-E.E-149
`CORNEIJS, G. -133-11.5-93
`CORONADO-MAGA, 1. — 20-K.K-21
`CORPOLONGO, A. - 166-LI-£82, 50-1.1-32
`
`Authors Index
`
`551
`
`CHAUHAN, s. — 11o-1.1-as
`CHAUVEAU, P. — 168-K.K-115
`CHAUVEL, M. — 61-c.C—45, 61—C.Cv47, 94-C.C~86
`CHAUVIN, 1.1». — 111-MN.MN-Z4
`CHAVANET, P. - 2I3—A.A—132, 52-1.1-so
`CHAVEZ, M. — 34-1.3-6
`CHAVIDEH, R. — 95~C.C-113
`CHEARSKUL, 5. — 126—I.I-144
`CHEEK, W. — 67-L.L—34
`CHEESE STUDY TEAM, THE — 125-1.1-133
`CHEEVER, L.w. — 141-1.1-178, 202-1.1-217
`CHEINGSONG, R. - 1241.1-113
`CHEINGSONGPOPOV, R. — 124-1.1-114
`CHEMINOT, N. — 166-1.]-186
`CHEN, C.Y. — 33~H.I-I-30
`CHEN, D. - 184~F.F-160
`CHEN, H. — 201-H.H-152
`CHEN, H.Y. — 48-F.F-34
`CHEN, K.S. — 188-J.J—122
`CHEN, M. — 200-EF-192, 200-F.F-193
`CHEN, R. - 107-G.G—50
`CHEN, R.T.-186-HH-131, 186-H.H-139,
`86-G.G-36
`CHEN, Y. — 149-F.F-127
`CHEN, z.w. — 50-1.!-25
`CHENE, G. — 123-1.1-152
`CHENG, A.1=. — 17-C.C-2o
`CHENG, A.F.B. - 179-K.K-122
`CHENG, D. - 43-11.13-zo
`CHENG, P. _ 31-G.G-22
`CHERNOFF, M.C. — 125-L1-130
`CHERNOUSOVA, LN. — 71-C.C-80
`CHERRTNGTON, J.M. — 124-1.1-123,63-1.1-84
`CHERRY, J.D. — 107-G.G-48
`CHERTOW, G. — 24-0.0-11
`CHESNEY, M. — 141-1., 141-1.1-168
`CHESNEY, MA. - 127—l.I-160
`CH1-:sNuT, R. — 186-H.H-143
`CHESNUT, R.W. — 164~G.G-93
`CHEUNG, 1. — 28-D.D-35
`CHEVAL, P. — 201-H.H-162
`CHEVALIER, C. — 100—E.E-72
`CHEVALIER, E}. — 145-A.A-77
`CHEVROLET, ].C. — 20-K.K—18
`CHHATWAL, 5. — 214-B.E-80
`CHIBA, K. — 198-A.A-123
`CHTBA, M. — l04—F.F-74
`_ CHIEN, 1. -92-AA-55
`: CHILLER, K. — 216-L!-267
`CH1LLER, T. - 2151.1-257
`CHTN, A.C. - 177-G.G-98
`CHIN, N.x. - 74-E.E-S6
`CHTVLICK, GE. — 13.7-A.A-73
`CHIU, B. — 4.1-13.3-21
`CHO, O. — 96-C.C-120
`CHO, D.T. - 70-C.C-56
`(H0, 111:. — L29-K.K- 71, m:.tLH- 157
`CHO1, H. -- 105-1=.1=-95
`CHO1, j.H. — 129-K.K-71
`CH01, 1.5. - 179-K.1<-125
`CHO1, Y.H. — 71-C.C-73
`CHOXSY, 1>. - 153-L.L-112
`CHOKEPHAIBULKIT, K. — 1291.1-144
`C1-TONG, Y. — 101-E.E-s5, 120-E.E-104, 44-D.O-4o
`CHOO, Y.S. —105-F.F~88, 105-F.F-89, 105-EE-9o,
`IG5~F.F-91, 105-8592, 105-5593, 105~F.F-94
`CHORUs PROGRAM TEAM, THE — 165-H.H-115.
`202-1.1-212
`C!-IOTPITAYASUNONDH, T. — 126-LI-144.
`CHOTIIN, C. -152-x.x-92
`_ CHOW, A.W. — 185-F.F«176, 135-E1=-177, 97—C.C-140
`CHOW, L. — 1o-13.13-7
`czcamructs, G. — 14421:,-17.
`CHR1sT1-:N, s. — 93-13.3-32
`CHRISTENSEN, 1.1. — 74~E_E-61
`CHRISTENSEN. K. _ 73-E.E.—46
`<:HR1sTEN5EN, 5.8. — 200-EE-192, 200-EE-193
`CHR1sTENsON, 1. — 23-LL-19
`. CHRISTMANN, D. — 144-L1.-91
`r.HR1sTOEALO, B. — 15-A.A-23, 15~A.A-30
`mR1sTO1>HERsON, C. — 205-1.1-250
`CHRN EH1 1NvEsT. GROUP, THE — use -1.1-135
`CHRYSSOUL1, z. — 214-3.579
`IHU, D. — 104-1=.1=-79, 104-F.F-81
`,D.T.W. - 104~F.F-86, 149-EF-125, 149—F.F-126,
`149-1~‘.1=~127
`.Y.w. — 179-K.K-122
`A, R. - 108-H.H-79
`
`
`
`-.1-J-1.-—..-....._-..:...1..-_...—-.1...--«.1-—..
`
`
`
`_
`
`3.D-92
`
`-l.H~112
`
`K.K-66
`
`-1.1-1433
`.F.-29
`
`C.C-87
`
`5-H.H-116,
`3-95
`
`133, 190-1<.K-134
`30-EE-15,
`:0
`
`186-H.H-132
`
`£.E»’).%
`
`L116!)
`56
`
`58-_).]-128
`
`

`
`
`
`
`
`xapuipin.-u\&a)q
`
`oxacillin resistance, C-133, C-147
`oxalidinone, F-137
`oxazolidinone, A-9, A-53, A-85, A-123, C-104,
`F.-124, E-129, F-129, F-130, F-131, F-138,
`F-139
`oxidative burst, [-38
`
`P P
`
`. aeruginosrz, B-51, E-85, G-104, K-72, K-73
`P. shigelloides, D-37
`P. stutzeri, C-123
`P. vulgaris, D-45
`P99 13-lactamase, C-165
`PacB, C-100
`pacemaker endocarditis, K-39
`paclitaxel, J-1 53
`PAN DR helper epitopes, G-93
`pancreatitis, D-113, L-93
`papillomavitus, H-31, H-50, H-147, H-158
`paracoccidioidomycosis, }- 142
`parasitic infections, G-109
`parenteral therapy, I-126, O-12
`partricins, 113-643, ]-64
`parvovirus B19, H-47
`Pasteurella, C-63, E-14.7
`pathogenesis, B-68, B-77, G-95, H-13, J-91
`patterns, E-168
`PEP 2’, F-12
`PBPS, C-3
`PCP, 1-144, [-269
`PC1’ prophylaxis, L-9
`PCR, D-24, D-30, D-33, D-34, D-63, D-124,
`H~22, H-43, H-65, H-92, H-113, H-122,
`H-148, I-1671),]-111, L-47, L-115, O-14d
`PCR detection, D-28
`PCR diagnosis, J‘-107
`'1-on finger yihnmg, 5-23
`‘PCR-REL? typing tnctlwds, E-76
`PCR-SSCP, D-106
`pediatric, A-S9, H-44, 1-3,1-4,l—145, l-180,
`L-36, L-94, M-38
`pediatric AIDS, I-7
`pediatric HIV, A—60, A-63
`pediatric HZV-1, I-11
`pediatric HIV-1 infection, l-153
`pediatric nosocomial, K-10%
`pediatric patients, M—2
`pediatrics, C-79, H.-64,1-5,1-9,1-147,1-150,
`K-46, L~31, L-127, M-40
`pefloxacin, A-95
`PEG, K-5 7
`PenR S. pneumoniae, B46
`penciclovir, H-10
`penetration, A-29
`penicillin, A-‘L, 0-103, 1.147, ‘E-13, M-7
`penicillin allergy, O-23
`penicillin resistance, A-132, C-20, C-76, E-8,
`E-9, E-46, K-I02
`penicillin resistant, C-15, E-26
`penicillin resistant pneumonia, C-18
`penicillin-binding proteins, F-17, F-22, F-41
`penicillin-nonsusceptible, E-16
`penicillin—R pneumococci, K-37b
`penicillin resistance, E10
`petticillin-resistant, B-35, E-47
`penicillin-susceptible, K-111
`penR pneumococci in USA, C-I8
`peptide, G-91, J-80
`peptide binding assay, F-164
`peptides, B-20, F-183
`peptidoglycan, K-37a
`perez, H-27
`petfluomocxyl bromide, A.-108
`
`Keyword Index
`
`651
`
`NNRTI, 1-12, I-102,1-103,1-104, I-237,1-244,
`I-245
`Nocardia, C-8
`nongonococcal urethritis, L’-69
`nontuberculous mycobacteria, I-205
`non-albicans Candida, J-25
`non-drug users, I-211
`non-Hodgkin’s lymphoma, I-265
`nonhuman primates, F-36
`nonfermenters, F-1 9
`nonfusing, L-71
`nonneutropenic, ]- 140
`NorA efflux pump, A-39
`noriloxacin, K-95
`nosocomial, E-95, H-79, K-8, K-9, K-21, K-45,
`K-48, K-60, K-63, K-86, K-1293, K-147
`nosocornial infection, E-85, E-104, }-25, ]-141,
`K-1, K-2, K-6, K-16, K-17, K-37, K-37'b,
`K-46, K-49a, K-61, K-92, K-100, K-112,
`K-136, K-137, K—138i), O-3
`nosocomial infections, }-31, K-18, K-41, K-67,
`K-81, K-83, K-127, K-148
`nosocoinial pneumonia, K-109, K-110, K-111,
`K-115
`nosocornial screening, D-56
`NOTFOUND, C-70, D-105, H-131, I-89,
`I-.260, J-943, K-138a, L-48, L-59
`novel diterpenoid, F-186
`NRTX, I-99
`nucleic acid amplification, D-125
`nucleoside analog, 1-208
`nucleotide insertion, C-10
`nucleotide sequence, C-11
`nursing homes, K-30
`
`O m
`
`tujpmivnal diseases, K-116
`occnpaniosmal esqpos-ore, E-156, K-133, K-134
`ocular lesions, K-62
`ocular toxoplasmosis, L66
`ofloxacin, M-36
`oligonucleotides, C-107, F-166
`omega-loop, C-168
`omeprazole, E-65
`oncogene, I-37
`one-step test kit, H-66
`onychoxnycosis. }-29, 141-23
`open clinical study, F-3, F-4, F-S, F-6
`opportunistic infections, H-38, 1-153, 1-163, 1-
`203, I-Z69
`oprD, C-127
`opsonin, J-86
`opsonophagocytosis, G-70, G-110
`oral, A-51
`oral carbagycnesn, ‘E-45
`oral cephalosporin, F-?., 13-3, 17-4 , 17-5, 13-6
`oral microflora, F-175
`orai mucositis, F-I75
`oral poiiovirus vaccine, H-142
`orophatyngeal candidiasis, 1-27, ]-130, 1-131,
`]-137, M-21
`orthopedic infections, K-33
`OspA vaccine, G-90
`oexeaarnyclitis, B-71, K- 51
`otitis, C-67
`otitis media, 021, G-49, M—35, M-36, M-37,
`M~38, M-40, M-41, M-42
`outbreak, K-23a, K-34, K-43, K-71, K-74,
`K-77, K-121, K-128, 1.-1, L-38, L-51
`outcome, E-164, l-1-114, 1-239, K-100, K-106,
`0-8, 0-13
`outpatient treatment, M-14
`oxacillin, D-53., D-64, D-67
`
`mycobacterial lymphadent, 1-264
`Mycobacterium avium, D-95, D-97, I-126
`Mycobacterium Avium Comp., L-19
`Mycobacterium celatum, B-57
`Mycobacterium fortuitum, K-143
`Mycobacterium genauense, I-135
`- Mycobacterium kansasii,1-139, L-20
`I Mycobacterinm Ieprae, F-185
`Mycobacterium sp., D-90
`Mycobactevium tuberculosis, D-85, D-97,
`D-99, D-120, D-121, D-122, D-125
`.
`g Mycoplasma, E-182, F-101
`' Mycoplasma hominis, C-43, E-31
`Mycoplasma pneumoniae, B-49, E-115, L-114
`mycoses, L-46
`mycosis, D-17
`myelitis/diagnosis, D-80
`
`NN
`
`I l1 l
`
`27
`
`. gononhoeae, D-35, D-41
`' N. meningitidis, E-46, G-51
`n-docosanol, H-91
`naphthyridones, I-14
`nasal carriage, L—7, M-3
`nasophatyngeal carriage, C-17, C-76, E-19
`nasopharyngeal specimens, H-66
`natural history, H-3, 1-5 7
`natural product, F-186
`NCCLS methods, F-104
`necrotizing enterocolitis, K-45
`necrotizing iasciitis, L-95, L-97
`Nef, l-43
`Neisseria gonorrboeae, C-54
`Neisseria menirzgitidis, E-47, G-67, L-30, L-34
`Neisseria spp., F-8
`' neffinavfg 11-11, 11- 7-1‘, {-2, {-59, I-68, I-I50,
`-
`1-195, 1-116, 1-24%, 5-249
`neonatal, B-1 1%, K-48
`neonatal XCU, K-75
`neonatal infections, L-96
`neonatal meningitis, L-33
`neonate, A-5 7, A-58, K-2, K-61
`neonates, A-61, G-89, K-23
`neopterin, 1-36
`nephrolithiasis, 1-59
`neplnroitoxicitjt, A-79, 9.457, A-8%, ‘1"r?.‘r, 3405,
`3,144, o-u
`nexilmicin, A-61
`' network, K-76
`neutaminidase inhibitor, H-58, 11-68
`fneurotoxicity, A-83, I-26, I-51
`iieutralization, I-27, I-167b
`beutralizing antibody, I-190
`].\eutro_penia_,_]-40,J-102,)-139, K—103_, K-103a
`be-.iszao5>laiil., G-64, G-69
`hentrophil function, G-62
`keutrophils, A-113, G-7, G-8, G-43, (3-98, 1-32
`’ §Ievirapine,1-64, I-97,1-195,1-Z26, I-248
`I
`‘new HIV inhibitors, [-23
`new Mycobacterium spp., E-43
`new quinolone, E-178, E-185, E-206, F-85,
`L-101
`new triazole, J-10
`tsiamle, ERAS-207147, F-1.54
`. at York, D-R1.
`. ‘cw Zealand, E-8
`'
`- om, K-17
`, er antirnicrobials. F-114
`
`
`
`-
`
`'
`'
`
`_
`-.
`
`_
`
`'
`
`-
`
`"T. ic oxide, B-5, B-15, B-32, B-52, G38, G46
`cel.ls.,1-53